• Explore /
  • Poster
  • / Clinical impact of discrepancy in PD-L1 expression on tumor cells between 22C3 and SP142 assay on the efficacy of pembrolizumab in advanced NSCLC patients.

Clinical impact of discrepancy in PD-L1 expression on tumor cells between 22C3 and SP142 assay on the efficacy of pembrolizumab in advanced NSCLC patients.

Abstract Poster

Authors

null

Jun Miyakoshi

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Jun Miyakoshi , Tatsuya Yoshida , Masayuki Shirasawa , Masahiro Torasawa , Yuji Matsumoto , Ken Masuda , Jumpei Kashima , Yuki Shinno , Yusuke Okuma , Yasushi Goto , Hidehito Horinouchi , Kouya Shiraishi , Takashi Kohno , Yasushi Yatabe , Noboru Yamamoto , Yuichiro Ohe

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics

Sub Track

Immunotherapies

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 145)

DOI

10.1200/GO.2023.9.Supplement_1.145

Abstract #

145

Poster Bd #

H7

Abstract Disclosures

Similar Posters

First Author: Rita Migliorino

First Author: Hiroshi Takumida

First Author: Renaud Descourt

First Author: Roberto Iacovelli